Glial cells in schizophrenia: pathophysiological significance and possible consequences for therapy

References

• Bogerts B. Schizophrenia. In: Encyclopedia of Neuroscience. Binder M, Hirokawa N, Windhorst U (Eds). Springer, Heidelberg, Germany (2009).
   Google Scholar
• Begre S, Koenig T. Cerebral disconnectivity: an early event in schizophrenia. Neuroscientist14(1), 19–45 (2008).
   PubMedGoogle Scholar
• Federspiel A, Begre S, Kiefer C, Schroth G, Strik WK, Dierks T. Alterations of white matter connectivity in first episode schizophrenia. Neurobiol. Dis.22(3), 702–709 (2006).
   PubMedGoogle Scholar
• Konrad A, Winterer G. Disturbed structural connectivity in schizophrenia primary factor in pathology or epiphenomenon? Schizophr. Bull.34(1), 72–92 (2008).
   PubMed Web of Science ®Google Scholar
• Walterfang M, Wood SJ, Velakoulis D, Pantelis C. Neuropathological, neurogenetic and neuroimaging evidence for white matter pathology in schizophrenia. Neurosci. Biobehav. Rev.30(7), 918–948 (2006).
   PubMed Web of Science ®Google Scholar
• Kubicki M, McCarley RW, Shenton ME. Evidence for white matter abnormalities in schizophrenia. Curr. Opin. Psychiatry18(2), 121–134 (2005).
   PubMedGoogle Scholar
• Ellison-Wright I, Bullmore E. Meta-analysis of diffusion tensor imaging studies in schizophrenia. Schizophr. Res.108(1–3), 3–10 (2009).
   PubMed Web of Science ®Google Scholar
• Dwork AJ, Mancevski B, Rosoklija G. White matter and cognitive function in schizophrenia. Int. J. Neuropsychopharmacol.10(4), 513–536 (2007).
   PubMedGoogle Scholar
• Regenold WT, Phatak P, Marano CM, Gearhart L, Viens CH, Hisley KC. Myelin staining of deep white matter in the dorsolateral prefrontal cortex in schizophrenia, bipolar disorder, and unipolar major depression. Psychiatry Res.151(3), 179–188 (2007).
   PubMed Web of Science ®Google Scholar
• Uranova NA, Orlovskaia DD, Vikhreva OV, Zimina IS, Rakhmanova VI. Morphometric study of ultrastructural changes in oligodendroglial cells in the postmortem brain in endogenous psychoses. Vestn. Ross. Akad. Med. Nauk (7), 42–48 (2001).
   PubMedGoogle Scholar
• Davis KL, Stewart DG, Friedman JI et al. White matter changes in schizophrenia: evidence for myelin-related dysfunction. Arch. Gen. Psychiatry60(5), 443–456 (2003).
   PubMed Web of Science ®Google Scholar
• Uranova NA, Vostrikov VM, Orlovskaya DD, Rachmanova VI. Oligodendroglial density in the prefrontal cortex in schizophrenia and mood disorders: a study from the Stanley Neuropathology Consortium. Schizophr. Res.67(2–3), 269–275 (2004).
   PubMed Web of Science ®Google Scholar
• Hof PR, Haroutunian V, Copland C, Davis KL, Buxbaum JD. Molecular and cellular evidence for an oligodendrocyte abnormality in schizophrenia. Neurochem. Res.27(10), 1193–1200 (2002).
   PubMed Web of Science ®Google Scholar
• Hof PR, Haroutunian V, Friedrich VL Jr et al. Loss and altered spatial distribution of oligodendrocytes in the superior frontal gyrus in schizophrenia. Biol. Psychiatry53(12), 1075–1085 (2003).
   PubMed Web of Science ®Google Scholar
• Byne W, Kidkardnee S, Tatusov A, Yiannoulos G, Buchsbaum MS, Haroutunian V. Schizophrenia-associated reduction of neuronal and oligodendrocyte numbers in the anterior principal thalamic nucleus. Schizophr. Res.85(1–3), 245–253 (2006).
   PubMed Web of Science ®Google Scholar
• Schmitt A, Steyskal C, Bernstein HG et al. Stereologic investigation of the posterior part of the hippocampus in schizophrenia. Acta Neuropathol.117(4), 395–407 (2009).
   PubMedGoogle Scholar
• Vostrikov VM, Uranova NA, Orlovskaya DD. Deficit of perineuronal oligodendrocytes in the prefrontal cortex in schizophrenia and mood disorders. Schizophr. Res.94(1–3), 273–280 (2007).
   PubMed Web of Science ®Google Scholar
• Vostrikov V, Orlovskaya D, Uranova N. Deficit of pericapillary oligodendrocytes in the prefrontal cortex in schizophrenia. World J. Biol. Psychiatry9(1), 34–42 (2008).
   PubMed Web of Science ®Google Scholar
• Uranova NA, Vostrikov VM, Vikhreva OV, Zimina IS, Kolomeets NS, Orlovskaya DD. The role of oligodendrocyte pathology in schizophrenia. Int. J. Neuropsychopharmacol.10(4), 537–545 (2007).
   PubMed Web of Science ®Google Scholar
• Uranova N, Bonartsev P, Brusov O, Morozova M, Rachmanova V, Orlovskaya D. The ultrastructure of lymphocytes in schizophrenia. World J. Biol. Psychiatry8(1), 30–37 (2007).
   PubMed Web of Science ®Google Scholar
• Martins-de-Souza D, Gattaz WF, Schmitt A et al. Proteomic analysis of dorsolateral prefrontal cortex indicates the involvement of cytoskeleton, oligodendrocyte, energy metabolism and new potential markers in schizophrenia. J. Psychiatr. Res. doi:10.1016/j.jpsychires.2008.11.006 (2008) (Epub ahead of print).
   PubMedGoogle Scholar
• Martins-de-Souza D, Gattaz WF, Schmitt A et al. Alterations in oligodendrocyte proteins, calcium homeostasis and new potential markers in schizophrenia anterior temporal lobe are revealed by shotgun proteome analysis. J. Neural Transm.116(3), 275–289 (2009).
   PubMed Web of Science ®Google Scholar
• Konopaske GT, Dorph-Petersen KA, Sweet RA et al. Effect of chronic antipsychotic exposure on astrocyte and oligodendrocyte numbers in macaque monkeys. Biol. Psychiatry63(8), 759–765 (2008).
   PubMed Web of Science ®Google Scholar
• McCullumsmith RE, Gupta D, Beneyto M et al. Expression of transcripts for myelination-related genes in the anterior cingulate cortex in schizophrenia. Schizophr. Res.90(1–3), 15–27 (2007).
   PubMed Web of Science ®Google Scholar
• Hakak Y, Walker JR, Li C et al. Genome-wide expression analysis reveals dysregulation of myelination-related genes in chronic schizophrenia. Proc. Natl Acad. Sci. USA98(8), 4746–4751 (2001).
   PubMed Web of Science ®Google Scholar
• Tkachev D, Mimmack ML, Ryan MM et al. Oligodendrocyte dysfunction in schizophrenia and bipolar disorder. Lancet362(9386), 798–805 (2003).
   PubMed Web of Science ®Google Scholar
• Aston C, Jiang L, Sokolov BP. Microarray analysis of postmortem temporal cortex from patients with schizophrenia. J. Neurosci. Res.77(6), 858–866 (2004).
   PubMed Web of Science ®Google Scholar
• Dracheva S, Davis KL, Chin B, Woo DA, Schmeidler J, Haroutunian V. Myelin-associated mRNA and protein expression deficits in the anterior cingulate cortex and hippocampus in elderly schizophrenia patients. Neurobiol. Dis.21(3), 531–540 (2006).
   PubMedGoogle Scholar
• Peirce TR, Bray NJ, Williams NM et al. Convergent evidence for 2’,3’-cyclic nucleotide 3’-phosphodiesterase as a possible susceptibility gene for schizophrenia. Arch. Gen. Psychiatry63(1), 18–24 (2006).
   PubMed Web of Science ®Google Scholar
• Katsel P, Davis KL, Haroutunian V. Variations in myelin and oligodendrocyte-related gene expression across multiple brain regions in schizophrenia: a gene ontology study. Schizophr. Res.79(2–3), 157–173 (2005).
   PubMed Web of Science ®Google Scholar
• Honer WG, Falkai P, Chen C, Arango V, Mann JJ, Dwork AJ. Synaptic and plasticity-associated proteins in anterior frontal cortex in severe mental illness. Neuroscience91(4), 1247–1255 (1999).
   PubMed Web of Science ®Google Scholar
• Flynn SW, Lang DJ, Mackay AL et al. Abnormalities of myelination in schizophrenia detected in vivo with MRI, and post-mortem with analysis of oligodendrocyte proteins. Mol. Psychiatry8(9), 811–820 (2003).
   PubMed Web of Science ®Google Scholar
• Chambers JS, Perrone-Bizzozero NI. Altered myelination of the hippocampal formation in subjects with schizophrenia and bipolar disorder. Neurochem. Res.29(12), 2293–2302 (2004).
   PubMed Web of Science ®Google Scholar
• Steiner J, Bernstein HG, Bielau H et al. S100B-immunopositive glia is elevated in paranoid as compared to residual schizophrenia: a morphometric study. J. Psychiatr. Res.42(10), 868–876 (2008).
   PubMed Web of Science ®Google Scholar
• Haroutunian V, Davis KL. Introduction to the special section: myelin and oligodendrocyte abnormalities in schizophrenia. Int. J. Neuropsychopharmacol.10(4), 499–502 (2007).
   PubMedGoogle Scholar
• Aberg K, Saetre P, Jareborg N, Jazin E. Human QKI, a potential regulator of mRNA expression of human oligodendrocyte-related genes involved in schizophrenia. Proc. Natl Acad. Sci. USA103(19), 7482–7487 (2006).
   PubMed Web of Science ®Google Scholar
• Aberg K, Saetre P, Lindholm E et al. Human QKI, a new candidate gene for schizophrenia involved in myelination. Am. J. Med. Genet. B Neuropsychiatr. Genet.141B(1), 84–90 (2006).
   PubMedGoogle Scholar
• Karoutzou G, Emrich HM, Dietrich DE. The myelin-pathogenesis puzzle in schizophrenia: a literature review. Mol. Psychiatry13(3), 245–260 (2008).
   PubMed Web of Science ®Google Scholar
• Zai G, King N, Wigg K et al. Genetic study of the myelin oligodendrocyte glycoprotein (MOG) gene in schizophrenia. Genes Brain Behav.4(1), 2–9 (2005).
   PubMedGoogle Scholar
• Voineskos AN, de Luca V, Bulgin NL et al. A family-based association study of the myelin-associated glycoprotein and 2’,3’-cyclic nucleotide 3’-phosphodiesterase genes with schizophrenia. Psychiatr. Genet.18(3), 143–146 (2008).
   PubMedGoogle Scholar
• Qu M, Yue W, Tang F, Wang L, Han Y, Zhang D. Polymorphisms of transferrin gene are associated with schizophrenia in Chinese Han population. J. Psychiatr. Res.42(11), 877–883 (2008).
   PubMedGoogle Scholar
• Corfas G, Roy K, Buxbaum JD. Neuregulin 1-erbB signaling and the molecular/cellular basis of schizophrenia. Nat. Neurosci.7(6), 575–580 (2004).
   PubMed Web of Science ®Google Scholar
• Sokolov BP. Oligodendroglial abnormalities in schizophrenia, mood disorders and substance abuse. Comorbidity, shared traits, or molecular phenocopies? Int. J. Neuropsychopharmacol.10(4), 547–555 (2007).
   PubMed Web of Science ®Google Scholar
• Buonanno A, Kwon OB, Yan L et al. Neuregulins and neuronal plasticity: possible relevance in schizophrenia. Novartis Found. Symp.289, 165–177 (2008).
   PubMedGoogle Scholar
• Talmage DA. Mechanisms of neuregulin action. Novartis Found. Symp.289, 74–84 (2008).
   PubMedGoogle Scholar
• Bertram I, Bernstein HG, Lendeckel U et al. Immunohistochemical evidence for impaired neuregulin-1 signaling in the prefrontal cortex in schizophrenia and in unipolar depression. Ann. NY Acad. Sci.1096, 147–156 (2007).
   PubMedGoogle Scholar
• Bernstein HG, Lendeckel U, Bertram I et al. Localization of neuregulin-1α (heregulin-α) and one of its receptors, ErbB-4 tyrosine kinase, in developing and adult human brain. Brain Res. Bull.69(5), 546–559 (2006).
   PubMedGoogle Scholar
• Birchmeier C. ErbB receptors and the development of the nervous system. Exp. Cell Res.315(4), 611–618 (2009).
   PubMedGoogle Scholar
• Chong VZ, Thompson M, Beltaifa S, Webster MJ, Law AJ, Weickert CS. Elevated neuregulin-1 and ErbB4 protein in the prefrontal cortex of schizophrenic patients. Schizophr. Res.100(1–3), 270–280 (2008).
   PubMedGoogle Scholar
• Hahn CG, Wang HY, Cho DS et al. Altered neuregulin 1-erbB4 signaling contributes to NMDA receptor hypofunction in schizophrenia. Nat. Med.12(7), 824–828 (2006).
   PubMed Web of Science ®Google Scholar
• Roy K, Murtie JC, El-Khodor BF et al. Loss of erbB signaling in oligodendrocytes alters myelin and dopaminergic function, a potential mechanism for neuropsychiatric disorders. Proc. Natl Acad. Sci. USA104(19), 8131–8136 (2007).
   PubMed Web of Science ®Google Scholar
• Georgieva L, Moskvina V, Peirce T et al. Convergent evidence that oligodendrocyte lineage transcription factor 2 (OLIG2) and interacting genes influence susceptibility to schizophrenia. Proc. Natl Acad. Sci. USA103(33), 12469–12474 (2006).
   PubMed Web of Science ®Google Scholar
• Mitkus SN, Hyde TM, Vakkalanka R et al. Expression of oligodendrocyte-associated genes in dorsolateral prefrontal cortex of patients with schizophrenia. Schizophr. Res.98(1–3), 129–138 (2008).
   PubMed Web of Science ®Google Scholar
• Novak G, Tallerico T. Nogo A, B and C expression in schizophrenia, depression and bipolar frontal cortex, and correlation of Nogo expression with CAA/TATC polymorphism in 3’-UTR. Brain Res.1120(1), 161–171 (2006).
   PubMed Web of Science ®Google Scholar
• Rothermundt M, Ponath G, Arolt V. S100B in schizophrenic psychosis. Int. Rev. Neurobiol59, 445–470 (2004).
   PubMed Web of Science ®Google Scholar
• Steiner J, Bernstein HG, Bielau H et al. Evidence for a wide extra-astrocytic distribution of S100B in human brain. BMC Neurosci.8(2), 2–12 (2007).
   PubMed Web of Science ®Google Scholar
• Steiner J, Bernstein HG, Bogerts B et al. S100B is expressed in, and released from, OLN-93 oligodendrocytes: influence of serum and glucose deprivation. Neuroscience154(2), 496–503 (2008).
   PubMedGoogle Scholar
• Lindholm E, Jazin E. A possible link between dopamine action and myelin dysfunction in schizophrenia. Schizophr. Res.96(1–3), 271–272 (2007).
   PubMedGoogle Scholar
• Tkachev D, Mimmack ML, Huffaker SJ, Ryan M, Bahn S. Further evidence for altered myelin biosynthesis and glutamatergic dysfunction in schizophrenia. Int. J. Neuropsychopharmacol.10(4), 557–563 (2007).
   PubMedGoogle Scholar
• Rosin C, Colombo S, Calver AA, Bates TE, Skaper SD. Dopamine D2 and D3 receptor agonists limit oligodendrocyte injury caused by glutamate oxidative stress and oxygen/glucose deprivation. Glia52(4), 336–343 (2005).
   PubMed Web of Science ®Google Scholar
• Carter CJ. Schizophrenia susceptibility genes converge on interlinked pathways related to glutamatergic transmission and long-term potentiation, oxidative stress and oligodendrocyte viability. Schizophr. Res.86(1–3), 1–14 (2006).
   PubMed Web of Science ®Google Scholar
• Franklin RJ. Why does remyelination fail in multiple sclerosis? Nat. Rev. Neurosci.3(9), 705–714 (2002).
   PubMed Web of Science ®Google Scholar
• Franklin RJ, Ffrench-Constant C. Remyelination in the CNS: from biology to therapy. Nat. Rev. Neurosci.9(11), 839–855 (2008).
   PubMed Web of Science ®Google Scholar
• Shen S, Sandoval J, Swiss VA et al. Age-dependent epigenetic control of differentiation inhibitors is critical for remyelination efficiency. Nat. Neurosci.11(9), 1024–1034 (2008).
   PubMed Web of Science ®Google Scholar
• Schmitz T, Chew LJ. Cytokines and myelination in the central nervous system. ScientificWorldJournal8, 1119–1147 (2008).
   PubMedGoogle Scholar
• Müller N, Schwarz M. Schizophrenia as an inflammation-mediated dysbalance of glutamatergic neurotransmission. Neurotox. Res.10(2), 131–148 (2006).
   PubMed Web of Science ®Google Scholar
• Potvin S, Stip E, Sepehry AA, Gendron A, Bah R, Kouassi E. Inflammatory cytokine alterations in schizophrenia: a systematic quantitative review. Biol. Psychiatry63, 801–808 (2008).
   PubMed Web of Science ®Google Scholar
• Seiwa C, Yamamoto M, Tanaka K et al. Restoration of FcRγ/Fyn signaling repairs central nervous system demyelination. J. Neurosci. Res.85(5), 954–966 (2007).
   PubMedGoogle Scholar
• Saetre P, Emilsson L, Axelsson E, Kreuger J, Lindholm E, Jazin E. Inflammation-related genes up-regulated in schizophrenia brains. BMC Psychiatry7, 46 (2007).
   PubMed Web of Science ®Google Scholar
• Chesik D, De Keyser J, Wilczak N. Insulin-like growth factor system regulates oligodendroglial cell behavior: therapeutic potential in CNS. J. Mol. Neurosci.35(1), 81–90 (2008).
   PubMedGoogle Scholar
• Xiao L, Xu H, Zhang Y et al. Quetiapine facilitates oligodendrocyte development and prevents mice from myelin breakdown and behavioral changes. Mol. Psychiatry13(7), 697–708 (2008).
   PubMed Web of Science ®Google Scholar
• Garver DL, Holcomb JA, Christensen JD. Compromised myelin integrity during psychosis with repair during remission in drug-responding schizophrenia. Int. J. Neuropsychopharmacol.11(1), 49–61 (2008).
   PubMed Web of Science ®Google Scholar
• Kimelberg HK. The problem of astrocyte identity. Neurochem. Int.45(2–3), 191–202 (2004).
   PubMed Web of Science ®Google Scholar
• Chan-Palay V, Palay SL. The form of velate astrocytes in the cerebellar cortex of monkey and rat: high voltage electron microscopy of rapid Golgi preparations. Z. Anat. Entwicklungsgesch.138(1), 1–19 (1972).
   PubMedGoogle Scholar
• Shehab SA, Cronly-Dillon JR, Nona SN, Stafford CA. Preferential histochemical staining of protoplasmic and fibrous astrocytes in rat CNS with GFAP antibodies using different fixatives. Brain Res.518(1–2), 347–352 (1990).
   PubMedGoogle Scholar
• Virchow R. Die Cellularpathologie in ihrer Begründung auf Physiologischer und Pathologischer Gewebelehre. August Hirschwald, Berlin, Germany (1858).
   Google Scholar
• De Keyser J, Mostert JP, Koch MW. Dysfunctional astrocytes as key players in the pathogenesis of central nervous system disorders. J. Neurol. Sci.267(1–2), 3–16 (2008).
   PubMed Web of Science ®Google Scholar
• Cotter DR, Pariante CM, Everall IP. Glial cell abnormalities in major psychiatric disorders: the evidence and implications. Brain Res. Bull.55(5), 585–595 (2001).
   PubMed Web of Science ®Google Scholar
• Stevens JR. Neuropathology of schizophrenia. Arch. Gen. Psychiatry39(10), 1131–1139 (1982).
   PubMed Web of Science ®Google Scholar
• Nasrallah HA, McCalley-Whitters M, Bigelow LB, Rauscher FP. A histological study of the corpus callosum in chronic schizophrenia. Psychiatry Res.8(4), 251–260 (1983).
   PubMedGoogle Scholar
• Bruton CJ, Crow TJ, Frith CD, Johnstone EC, Owens DG, Roberts GW. Schizophrenia and the brain: a prospective clinico-neuropathological study. Psychol. Med.20(2), 285–304 (1990).
   PubMed Web of Science ®Google Scholar
• Roberts GW, Colter N, Lofthouse R, Bogerts B, Zech M, Crow TJ. Gliosis in schizophrenia: a survey. Biol. Psychiatry21(11), 1043–1050 (1986).
   PubMedGoogle Scholar
• Bogerts B. Recent advances in the neuropathology of schizophrenia. Schizophr. Bull.19(2), 431–445 (1993).
   PubMed Web of Science ®Google Scholar
• Arnold SE, Franz BR, Trojanowski JQ, Moberg PJ, Gur RE. Glial fibrillary acidic protein-immunoreactive astrocytosis in elderly patients with schizophrenia and dementia. Acta Neuropathol.91(3), 269–277 (1996).
   PubMedGoogle Scholar
• Falkai P, Honer WG, David S, Bogerts B, Majtenyi C, Bayer TA. No evidence for astrogliosis in brains of schizophrenic patients. A post-mortem study. Neuropathol. Appl. Neurobiol.25(1), 48–53 (1999).
   PubMedGoogle Scholar
• Damadzic R, Bigelow LB, Krimer LS et al. A quantitative immunohistochemical study of astrocytes in the entorhinal cortex in schizophrenia, bipolar disorder and major depression: absence of significant astrocytosis. Brain Res. Bull.55(5), 611–618 (2001).
   PubMedGoogle Scholar
• Falkai P, Bogerts B. Cell loss in the hippocampus of schizophrenics. Eur. Arch. Psychiatry Neurol. Sci.236(3), 154–161 (1986).
   PubMedGoogle Scholar
• Pakkenberg B. Pronounced reduction of total neuron number in mediodorsal thalamic nucleus and nucleus accumbens in schizophrenics. Arch. Gen. Psychiatry47(11), 1023–1028 (1990).
   PubMed Web of Science ®Google Scholar
• Rajkowska G, Miguel-Hidalgo JJ, Makkos Z, Meltzer H, Overholser J, Stockmeier C. Layer-specific reductions in GFAP-reactive astroglia in the dorsolateral prefrontal cortex in schizophrenia. Schizophr. Res.57(2–3), 127–138 (2002).
   PubMed Web of Science ®Google Scholar
• Oifa AI, Uranova NA. Electron-microscopic analysis of cytoarchitectonic disorders in the cerebral cortex in schizophrenia. Zh. Nevropatol. Psikhiatr. Im. S. S. Korsakova91(10), 48–52 (1991).
   PubMedGoogle Scholar
• Kolomeets NS. Astroglia of the hippocampus in schizophrenia. Zh. Nevropatol. Psikhiatr. Im. S. S. Korsakova108(4), 70–76 (2008).
   Google Scholar
• Webster MJ, O’Grady J, Kleinman JE, Weickert CS. Glial fibrillary acidic protein mRNA levels in the cingulate cortex of individuals with depression, bipolar disorder and schizophrenia. Neuroscience133(2), 453–461 (2005).
   PubMed Web of Science ®Google Scholar
• Steffek AE, McCullumsmith RE, Haroutunian V, Meador-Woodruff JH. Cortical expression of glial fibrillary acidic protein and glutamine synthetase is decreased in schizophrenia. Schizophr. Res.103(1–3), 71–82 (2008).
   PubMed Web of Science ®Google Scholar
• Bruneau EG, McCullumsmith RE, Haroutunian V, Davis KL, Meador-Woodruff JH. Increased expression of glutaminase and glutamine synthetase mRNA in the thalamus in schizophrenia. Schizophr. Res.75(1), 27–34 (2005).
   PubMedGoogle Scholar
• Toro CT, Hallak JE, Dunham JS, Deakin JF. Glial fibrillary acidic protein and glutamine synthetase in subregions of prefrontal cortex in schizophrenia and mood disorder. Neurosci. Lett.404(3), 276–281 (2006).
   PubMed Web of Science ®Google Scholar
• Stevens B. Neuron-astrocyte signaling in the development and plasticity of neural circuits. Neurosignals16(4), 278–288 (2008).
   PubMedGoogle Scholar
• Haydon PG. GLIA: listening and talking to the synapse. Nat. Rev. Neurosci.2(3), 185–193 (2001).
   PubMed Web of Science ®Google Scholar
• Theberge J, Williamson KE, Aoyama N et al. Longitudinal grey-matter and glutamatergic losses in first-episode schizophrenia. Br. J. Psychiatry191, 325–334 (2007).
   PubMedGoogle Scholar
• Hashimoto K, Engberg G, Shimizu E, Nordin C, Lindstrom LH, Iyo M. Elevated glutamine/glutamate ratio in cerebrospinal fluid of first episode and drug naive schizophrenic patients. BMC Psychiatry5, 6 (2005).
   PubMed Web of Science ®Google Scholar
• Myint AM, Kim YK, Verkerk R et al. Tryptophan breakdown pathway in bipolar mania. J. Affect. Disord.102(1–3), 65–72 (2007).
   PubMed Web of Science ®Google Scholar
• Baslow MH. The astrocyte surface NAAG receptor and NAAG peptidase signaling complex as a therapeutic target. Drug News Perspect.21(5), 251–257 (2008).
   PubMedGoogle Scholar
• Brisch R, Bernstein HG, Krell D et al. Dopamine-glutamate abnormalities in the frontal cortex associated with the catechol-O-methyltransferase (COMT) in schizophrenia. 1269, 166–175 Brain Res. (2009).
   PubMedGoogle Scholar
• Owen F, Crow TJ, Frith CD et al. Selective decreases in MAO-B activity in post-mortem brains from schizophrenic patients with type II syndrome. Br. J. Psychiatry151, 514–519 (1987).
   PubMedGoogle Scholar
• Kondziella D, Brenner E, Eyjolfsson EM, Sonnewald U. How do glial-neuronal interactions fit into current neurotransmitter hypotheses of schizophrenia? Neurochem. Int.50(2), 291–301 (2007).
   PubMedGoogle Scholar
• Gorwood P, Pouchot J, Vinceneux P et al. Rheumatoid arthritis and schizophrenia: a negative association at a dimensional level. Schizophr. Res.66(1), 21–29 (2004).
   PubMed Web of Science ®Google Scholar
• Wagner-Jauregg J. Über die Einwirkung fieberhafter Erkrankungen auf Psychosen. Allgemeine Z. Psychiatrie27, 93–131 (1887).
   Google Scholar
• Nunes SO, Borelli SD, Matsuo T, Watanabe MA, Itano EN. The association of the HLA in patients with schizophrenia, schizoaffective disorder, and in their biological relatives. Schizophr. Res.76(2–3), 195–198 (2005).
   PubMedGoogle Scholar
• Torrey EF, Leweke MF, Schwarz MJ et al. Cytomegalovirus and schizophrenia. CNS Drugs20(11), 879–885 (2006).
   PubMed Web of Science ®Google Scholar
• Yolken RH, Torrey EF. Viruses, schizophrenia, and bipolar disorder. Clin. Microbiol. Rev.8(1), 131–145 (1995).
   PubMed Web of Science ®Google Scholar
• Torrey EF, Bartko JJ, Lun ZR, Yolken RH. Antibodies to Toxoplasma gondii in patients with schizophrenia: a meta-analysis. Schizophr. Bull.33(3), 729–736 (2007).
   PubMed Web of Science ®Google Scholar
• Babulas V, Factor-Litvak P, Goetz R, Schaefer CA, Brown AS. Prenatal exposure to maternal genital and reproductive infections and adult schizophrenia. Am. J. Psychiatry163(5), 927–929 (2006).
   PubMed Web of Science ®Google Scholar
• Brown AS. The risk for schizophrenia from childhood and adult infections. Am. J. Psychiatry165(1), 7–10 (2008).
   PubMedGoogle Scholar
• Nyffeler M, Meyer U, Yee BK, Feldon J, Knuesel I. Maternal immune activation during pregnancy increases limbic GABAA receptor immunoreactivity in the adult offspring: implications for schizophrenia. Neuroscience143(1), 51–62 (2006).
   PubMedGoogle Scholar
• Arolt V, Rothermundt M. The immunology of psychiatric disorders. Psychother. Psychosom. Med. Psychol.55(1), 36–48 (2005).
   PubMedGoogle Scholar
• Drzyzga L, Obuchowicz E, Marcinowska A, Herman ZS. Cytokines in schizophrenia and the effects of antipsychotic drugs. Brain Behav. Immun.20(6), 532–545 (2006).
   PubMed Web of Science ®Google Scholar
• Schuld A, Hinze-Selch D, Pollmaecher T. Cytokine network in patients with schizophrenia and its significance for the pathophysiology of the illness. Nervenarzt75(3), 215–226 (2004).
   PubMed Web of Science ®Google Scholar
• Sperner-Unterweger B. Immunological aetiology of major psychiatric disorders: evidence and therapeutic implications. Drugs65(11), 1493–1520 (2005).
   PubMed Web of Science ®Google Scholar
• Conejero-Goldberg C, Torrey EF, Yolken RH. Herpes viruses and Toxoplasma gondii in orbital frontal cortex of psychiatric patients. Schizophr. Res.60(1), 65–69 (2003).
   PubMedGoogle Scholar
• Bayer TA, Buslei R, Havas L, Falkai P. Evidence for activation of microglia in patients with psychiatric illnesses. Neurosci. Lett.271(2), 126–128 (1999).
   PubMed Web of Science ®Google Scholar
• Radewicz K, Garey LJ, Gentleman SM, Reynolds R. Increase in HLA-DR immunoreactive microglia in frontal and temporal cortex of chronic schizophrenics. J. Neuropathol. Exp. Neurol.59(2), 137–150 (2000).
   PubMedGoogle Scholar
• Wierzba-Bobrowicz T, Lewandowska E, Lechowicz W, Stepien T, Pasennik E. Quantitative analysis of activated microglia, ramified and damage of processes in the frontal and temporal lobes of chronic schizophrenics. Folia Neuropathol.43(2), 81–89 (2005).
   PubMed Web of Science ®Google Scholar
• Arnold SE, Trojanowski JQ, Gur RE, Blackwell P, Han LY, Choi C. Absence of neurodegeneration and neural injury in the cerebral cortex in a sample of elderly patients with schizophrenia. Arch. Gen. Psychiatry55(3), 225–232 (1998).
   PubMedGoogle Scholar
• Falke E, Han LY, Arnold SE. Absence of neurodegeneration in the thalamus and caudate of elderly patients with schizophrenia. Psychiatry Res.93(2), 103–110 (2000).
   PubMedGoogle Scholar
• Kurumaji A, Wakai T, Toru M. Decreases in peripheral-type benzodiazepine receptors in postmortem brains of chronic schizophrenics. J. Neural Transm.104(11–12), 1361–1370 (1997).
   PubMedGoogle Scholar
• Steiner J, Bielau H, Brisch R et al. Immunological aspects in the neurobiology of suicide: elevated microglial density in schizophrenia and depression is associated with suicide. J. Psychiatr. Res.42(2), 151–157 (2008).
   PubMed Web of Science ®Google Scholar
• Steiner J, Mawrin C, Ziegeler A et al. Distribution of HLA-DR-positive microglia in schizophrenia reflects impaired cerebral lateralization. Acta Neuropathol.112(3), 305–316 (2006).
   PubMed Web of Science ®Google Scholar
• Togo T, Akiyama H, Kondo H et al. Expression of CD40 in the brain of Alzheimer’s disease and other neurological diseases. Brain Res.885(1), 117–121 (2000).
   PubMedGoogle Scholar
• Wierzba-Bobrowicz T, Lewandowska E, Kosno-Kruszewska E, Lechowicz W, Pasennik E, Schmidt-Sidor B. Degeneration of microglial cells in frontal and temporal lobes of chronic schizophrenics. Folia Neuropathol.42(3), 157–165 (2004).
   PubMedGoogle Scholar
• Mittelbronn M, Dietz K, Schluesener HJ, Meyermann R. Local distribution of microglia in the normal adult human central nervous system differs by up to one order of magnitude. Acta Neuropathol. (Berl.)101(3), 249–255 (2001).
   PubMed Web of Science ®Google Scholar
• Mattiace LA, Davies P, Dickson DW. Detection of HLA-DR on microglia in the human brain is a function of both clinical and technical factors. Am. J. Pathol.136(5), 1101–1114 (1990).
   PubMed Web of Science ®Google Scholar
• Rogers J, Luber-Narod J, Styren SD, Civin WH. Expression of immune system-associated antigens by cells of the human central nervous system: relationship to the pathology of Alzheimer’s disease. Neurobiol. Aging9(4), 339–349 (1988).
   PubMed Web of Science ®Google Scholar
• van Berckel BN, Bossong MG, Boellaard R et al. Microglia activation in recent-onset schizophrenia: a quantitative (R)-[11C]PK11195 positron emission tomography study. Biol. Psychiatry64(9), 820–822 (2008).
   PubMed Web of Science ®Google Scholar
• Hirsch S. Clinical changes measured by [11C](R)-PK11195 PET in patients with psychosis and cognitive decline are associated with impaired event related potential mismatch negativity. (Abstract from the 12th Biennial Winter workshop on Schizophrenia, Davos, Switzerland). Schizophr. Res.67(Suppl. 1), 103 (2004).
   Google Scholar
• Miyaoka T, Yasukawa R, Yasuda H, Hayashida M, Inagaki T, Horiguchi J. Possible antipsychotic effects of minocycline in patients with schizophrenia. Prog. Neuropsychopharmacol. Biol. Psychiatry31(1), 304–307 (2007).
   PubMed Web of Science ®Google Scholar
• Seibert K, Zhang Y, Leahy K, Hauser S, Masferrer J, Isakson P. Distribution of COX-1 and COX-2 in normal and inflamed tissues. Adv. Exp. Med. Biol.400A, 167–170 (1997).
   PubMedGoogle Scholar
• O’Banion MK. Cyclooxygenase-2: molecular biology, pharmacology, and neurobiology. Crit. Rev. Neurobiol.13(1), 45–82 (1999).
   PubMed Web of Science ®Google Scholar
• Akhondzadeh S, Tabatabaee M, Amini H, Ahmadi Abhari SA, Abbasi SH, Behnam B. Celecoxib as adjunctive therapy in schizophrenia: a double-blind, randomized and placebo-controlled trial. Schizophr. Res.90(1–3), 179–185 (2007).
   PubMed Web of Science ®Google Scholar
• Müller N, Ulmschneider M, Scheppach C et al. COX-2 inhibition as a treatment approach in schizophrenia: immunological considerations and clinical effects of celecoxib add-on therapy. Eur. Arch. Psychiatry Clin. Neurosci.254(1), 14–22 (2004).
   PubMed Web of Science ®Google Scholar
• Müller N, Riedel M, Scheppach C et al. Beneficial antipsychotic effects of celecoxib add-on therapy compared to risperidone alone in schizophrenia. Am. J. Psychiatry159(6), 1029–1034 (2002).
   PubMed Web of Science ®Google Scholar
• Müller N, Riedel M, Schwarz MJ, Engel RR. Clinical effects of COX-2 inhibitors on cognition in schizophrenia. Eur. Arch. Psychiatry Clin. Neurosci.255(2), 149–151 (2005).
   PubMed Web of Science ®Google Scholar
• Rapaport MH, Delrahim KK, Bresee CJ, Maddux RE, Ahmadpour O, Dolnak D. Celecoxib augmentation of continuously ill patients with schizophrenia. Biol. Psychiatry57(12), 1594–1596 (2005).
   PubMed Web of Science ®Google Scholar
• Maida ME, Hurley SD, Daeschner JA, Moore AH, O’Banion MK. Cytosolic prostaglandin E2 synthase (cPGES) expression is decreased in discrete cortical regions in psychiatric disease. Brain Res.1103(1), 164–172 (2006).
   PubMed Web of Science ®Google Scholar
• Stolk P, Souverein PC, Leufkens HG, Weil JG, Egberts AC, Heerdink ER. The association between exposure to COX-2 inhibitors and schizophrenia deterioration. A nested case–control study. Pharmacopsychiatry40(3), 111–115 (2007).
   PubMed Web of Science ®Google Scholar